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Abstract
Hemorrhagic fevers caused by arenaviruses are among the most devastating emerging human
diseases. Considering the number of individuals affected, the current lack of a licensed vaccine,
and the limited therapeutic options, arenaviruses are arguable among the most neglected tropical
pathogens and the development of efficacious anti-arenaviral drugs is of high priority. Over the
past years significant efforts have been undertaken to identify novel potent inhibitors of arenavirus
infection. High throughput screening of small molecule libraries employing pseudotype platforms
led to the discovery of several potent and broadly active inhibitors of arenavirus cell entry that are
effective against the major hemorrhagic arenaviruses. Mechanistic studies revealed that these
novel entry inhibitors block arenavirus membrane fusion and provided novel insights into the
unusual mechanism of this process. The success of these approaches highlights the power of small
molecule screens in antiviral drug discovery and establishes arenavirus membrane fusion as a
robust drug target. These broad screenings have been complemented by strategies targeting
cellular factors involved in productive arenavirus infection. Approaches targeting the cellular
protease implicated in maturation of the fusion-active viral envelope glycoprotein identified the
proteolytic processing of the arenavirus glycoprotein precursor as a novel and promising target for
anti-arenaviral strategies.
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Introduction
Arenaviruses are important emerging human pathogens
Several arenaviruses cause severe viral hemorrhagic fevers (VHF) in humans and represent
a serious public health problem (Geisbert and Jahrling, 2004). Lassa virus (LASV) in Africa
causes several hundred thousand infections per year resulting in significant mortality and
morbidity (McCormick and Fisher-Hoch, 2002). On the South American continent, the
arenaviruses Junin (JUNV), Machupo (MACV), Guanarito (GTOV), and Sabia virus
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(SABV) have emerged as etiological agents of severe VHF in Argentina, Venezuela,
Bolivia, and Brazil, respectively (Buchmeier, de la Torre, and Peters, 2007). The worldwide-
distributed prototypic arenavirus lymphocytic choriomeningitis virus (LCMV) is also a
neglected human pathogen of clinical significance, especially in pediatric medicine (Barton,
Mets, and Beauchamp, 2002) and represents a threat to immuno-compromised individuals,
as tragically illustrated by recent fatal cases of transplant-acquired LCMV infection (Fischer
et al., 2006; Palacios et al., 2008). New arenaviruses emerge on average every three years as
illustrated by the recent discoveries of Chapare virus and Lujo virus that were associated
with fatal hemorrhagic fever cases in Bolivia and Southern Africa, respectively (Briese et
al., 2009; Delgado et al., 2008).
A hallmark of fatal arenavirus VHF is marked immunosuppression of the host and
consequent uncontrolled fatal infection (Geisbert and Jahrling, 2004). Those who survive
develop a vigorous anti-viral immune response during the second week of disease, control
the infection, and ultimately clear the virus. Control of acute arenavirus infection appears to
be primarily associated with cellular immunity rather than neutralizing antibodies (Fisher-
Hoch and McCormick, 2004; McCormick and Fisher-Hoch, 2002). Neutralizing antibodies
appear during convalescence and are in case of Lassa fever frequently of low titer. A highly
predictive factor for disease outcome in arenavirus VHF is the viral load, indicating a close
competition between viral spread and replication and the patient s immune
system(McCormick and Fisher-Hoch, 2002). Anti-viral drugs that limit viral replication and
spread may provide the patient s immune system a window of opportunity to develop anti-
viral immune responses, to control, and ultimately clear the virus. The development of novel
drugs targeting different steps in the arenavirus life cycle is therefore a promising strategy to
combat arenavirus infection in humans and will be covered in the present review.
Molecular and cell biology of arenaviruses
The molecular and cell biology of arenaviruses has been covered by excellent recent reviews
(Buchmeier, de la Torre, and Peters, 2007; de la Torre, 2009) and only a short summary will
be given here. Arenaviruses are enveloped viruses with a bisegmented negative strand RNA
genome and a life cycle restricted to the cytoplasm. Each genomic RNA segment L (ca 7.3
kb) and S (ca 3.5 kb) uses an ambisense coding strategy to direct the synthesis of two
polypeptides in opposite orientation, separated by a non-coding intergenic region (IGR) with
a predicted hairpin structure (Fig. 1). The S RNA encodes the viral glycoprotein precursor,
GPC, and the nucleoprotein, NP, (ca 63 kDa), whereas the L RNA encodes the viral RNA
dependent RNA polymerase (RdRp, or L polymerase) (ca 200 kDa), and a small RING
finger protein Z (ca 11 kDa). Arenavirus GPC is synthesized as a single polypeptide chain
(ca 75 kDa) and post-translationally cleaved by the cellular proprotein convertase (PC)
subtilisin kexin isozyme-1 (SKI-1)/site-1 protease (S1P) to yield the mature virion
glycoproteins GP1 (40-46 kDa) and GP2 (35 kDa) (Beyer et al., 2003; Lenz et al., 2001;
Pinschewer et al., 2003; Rojek et al., 2008a). The GP1 part mediates virus interaction with
host cell surface receptors and is located at the top of the mature GP spike present in the
viral envelope. GP1 is associated via ionic interactions with the transmembrane GP2 that
forms the stalk of the spike. Arenavirus GP2 resembles the fusion-active membrane-
proximal parts of other enveloped viruses. The cellular receptor for LASV and most isolates
of LCMV is α-dystroglycan (α-DG), a cell surface receptor for proteins of the extracellular
matrix (ECM) (Cao et al., 1998). The New World arenaviruses JUNV, MACV, GTOV, and
SABV can use human transferrin receptor 1 (TfR1) as a cellular receptor (Radoshitzky et al.,
2007). Upon attachment to the target cell, arenavirus particles are taken up by endocytosis
and delivered to acidified endosomes where low pH induces membrane fusion (Borrow and
Oldstone, 1994). New World arenaviruses like JUNV that use human TfR1 enter the cell via
clathrin-mediated endocytosis (Martinez, Cordo, and Candurra, 2007). In contrast, the Old
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World arenaviruses LASV and LCMV, which depend on α-DG, use a distinct and unusual
pathway for cell entry that is independent of clathrin, caveolin, dynamin, and actin and
bypasses classical routes of incoming early endosomal trafficking (Quirin et al., 2008;
Rojek, Perez, and Kunz, 2008; Rojek et al., 2008b).
Formation and release of arenavirus infectious progeny from infected cells by budding
requires that assembled viral RNPs associate at the cell surface with membranes that are
enriched in viral GPs. For many enveloped RNA viruses viral budding is mediated by a
matrix (M) protein that acts as a bridge between the RNP and GP. In arenaviruses, the Z
protein functions as the main driving force of arenavirus budding (Perez, Craven, and de la
Torre, 2003; Strecker et al., 2003) and the process is mediated by the Z proline-rich late (L)
domain motifs (PTAP and PPPY) known to control budding of several other viruses via
interaction with specific host cell proteins (Freed, 2002).
Current drugs to combat arenaviruses
The only licensed drug for treatment of human arenavirus infection is the nucleoside
analogue ribavirin (Rib) (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) (Parker, 2005).
In vitro and in vivo studies have documented the prophylactic and therapeutic value of Rib
against several arenaviruses. Rib reduced both morbidity and mortality in humans associated
with LASV infection (McCormick et al., 1986), and experimentally in MACV (Kilgore et
al., 1995) and JUNV (Weissenbacher, Laguens, and Coto, 1987) infections, if given early in
the course of clinical disease. The mechanism of action of Rib against arenaviruses is
currently not entirely clear. Studies in the LCMV model revealed that the anti-viral effect of
Rib is not associated with significant increases in virus mutation frequencies, but has a
dramatic effect on viral RNA synthesis (Ruiz-Jarabo et al., 2003) Over the past two decades
efforts have been made to discover novel drug candidates to combat arenaviruses and only a
short and by no means comprehensive overview can be given here: Inhibitors of IMP
dehydrogenase (Andrei and De Clercq, 1993), the S-adenosylhomocysteine (SAH)
hydrolase (Andrei and De Clercq, 1990), phenotiazines compounds (Candurra, Maskin, and
Damonte, 1996), brassinosteroids (Wachsman et al., 2000) and myristic acid (Cordo,
Candurra, and Damonte, 1999) have been reported to have anti-arenaviral activity. Several
zinc-finger-reactive compounds with antiretroviral potential showed activity against
arenaviruses (Garcia, Candurra, and Damonte, 2000; Garcia et al., 2006) and evidence has
been provided for an involvement of the viral Z protein in their mechanism of action (Garcia
et al., 2010). The pyrazine derivative T-705 (6-fluoro-3-hydrody-2-pyrazinecarboxamide)
showed activity against the arenaviruses JUNV, Pichinde (PICV), and Tacaribe virus
(TACV) in vitro and protected against PICV infection in a hamster model (Gowen et al.,
2007), with efficacy in late stage infection (Gowen et al., 2008).
Early attempts to target arenavirus entry employed sulfated polysaccharides (Andrei and De
Clercq, 1990) and revealed inhibitory effects of charged polymers on arenavirus infection,
however, the exact mechanism of action remained elusive. A more recent study evaluated
phosphorothioate oligonucleotides in the LCMV model and revealed that amphipathic DNA
polymers are potent inhibitors of arenavirus infection (Lee et al., 2008). The DNA polymers
act at the level of cell entry and target the interaction between LCMVGP and its cellular
receptor, α-DG, without affecting later steps in replication. While these studies are of great
value as proof-of-principle, to the best of our knowledge none of these drug candidates has
undergone further evaluation in pre-clinical and clinical trials.
Discovery of novel inhibitors of arenavirus entry by small molecule screening
Since entry into the host cell is the first step of every virus infection it represents a
promising target for attacking the virus before it can gain control over the host cell
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machinery for replication. In recent years, viral entry inhibitors have emerged as a new class
of anti-viral drugs, with enfuvirtide being successfully used for clinical treatment of humans
infected with human immunodeficiency virus (HIV) (Este and Telenti, 2007; Qian, Morris-
Natschke, and Lee, 2009) and potent small molecule inhibitors for entry of other viruses,
including influenza (Vanderlinden et al., 2010) and hepatitis C virus (Baldick et al., 2010)
have been reported.
Considering the limited public health infrastructure in endemic regions, highest priority is
given to the development of novel synthetic drugs against human pathogenic arenaviruses
that can be produced at low cost, delivered orally, and can be stored in tropical climates. To
achieve this goal, several attempts at drug discovery based on screening large collections of
synthetic small molecules have been undertaken. High throughput screening (HTS) of small
molecular libraries has emerged as a major source of potent agonists and antagonists for a
great number of molecular interaction implicated in a variety biochemical processes (Boger,
Desharnais, and Capps, 2003). Despite the possible involvement of several molecular
interfaces, a large number of studies on protein-protein interaction indicate that in most
cases, small clusters of amino acid residues mediate the energetically most important
interactions (Livnah et al., 1996; Wells, 1996; Wells and de Vos, 1996; Wrighton et al.,
1996) that may be perturbed by small synthetic molecules. Libraries of small molecules can
therefore be used to screen for and identify molecules that promote protein–protein
interactions (agonists) or inhibit protein–protein interactions (antagonists) (Boger et al.,
1998).
A first attempt using HTS of small molecules to identify inhibitors of arenavirus infection
employed a virus-induced cytopathic effect (CPE)-based assay involving the non-pathogenic
New World arenavirus TACV. HTS of a random library identified a potent small molecule
inhibitor of TACV and several other New World arenaviruses, ST-294 (Fig. 2) (Bolken et
al., 2006), providing proof-of-principle for the feasibility of this type of approach.
All hemorrhagic arenaviruses are classified as biosafety level (BSL)-4 pathogens requiring
high security containment laboratories for work with live viruses. In order to identify
specific inhibitors of cell entry of hemorrhagic arenaviruses, subsequent drug screening
strategies made use of recombinant retroviruses bearing the GP of hemorrhagic arenaviruses
in their envelope and a luciferase reporter in their genome (Larson et al., 2008; Lee et al.,
2008). Since arenavirus cell attachment and entry are mediated exclusively by the envelope
GP, these pseudotype platforms allow rapid and reliable screening of small molecule
libraries in a HTS format. On one study, pre-selected combinatorial small molecule libraries
were chosen instead of random libraries, allowing a significant reduction of the scope of the
screen to less than 100,000 compounds. Combinatorial chemical libraries generated by
solution-phase synthetic techniques (Boger et al., 1998) have proven to be powerful sources
of novel inhibitors or agonists of a variety of biochemical interactions. The use of this type
of library has identified erythropoieitin (EPO) mimetics (promote EPO receptor
dimerization) (Berg et al., 2002), inhibitors of Myc/Max dimerization (Berg et al., 2002),
inhibitors of LEF-1/β-catenin dimerization (Boger et al., 2000), inhibitors of the binding of
the protease MMP-2 to αvβ3 integrin (Boger et al., 2001; Silletti et al., 2001), and inhibitors
of HIV protease (Chang et al., 2010). Positive screening of circa 80,000 compounds with
LASV pseudotypes yielded initially circa 1 % hits (Lee et al., 2008). Based on the
combinatorial nature of the libraries, the hits tended to appear in clusters of structurally
related compounds. Counter-screening employing pseudotypes of the unrelated vesicular
stomatitis virus (VSV) yielded 32 single compounds and 53 mixtures of 4- to 10 compounds
each that specifically blocked LASV GP-mediated infection. A series of leads were selected,
including the candidate compounds 8C1 and 17C8 (Fig 2). Candidate compounds 8C1 and
17C8 efficiently blocked infection of cells with live LASV, whereas candidate 17C8, but not
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8C1 was also potent against JUNV and other New World hemorrhagic arenaviruses with
comparable IC50 values. Mechanistic studies revealed that both 8C1 and 17C8 blocked the
very last step of viral entry, pH-dependent membrane fusion. When tested in a cell-based
arenavirus GP fusion assay, these compounds efficiently blocked membrane fusion mediated
by the GPs of LASV and JUNV with an IC50 between 200-350 nM. The combinatorial
nature of the chemical libraries allowed the identification of clusters of structurally related
compounds with differential anti-viral activity, providing the basis for a first assessment of
structure-activity-relationship (SAR). Subsequent examination of selected compounds in the
same series as 17C8 and the related 16G8 (Fig. 2) identified several additional candidates
that exhibited potent activity against LASV GP-mediated infection (Whitby et al., 2009).
These compounds showed that the benzofuran and the X-benzyl moieties (X being either
methyl- or methoxy-) impart the activity of the compound against the LASV GP, as
substitution at the third position around the central ring of various different-sized
substituents, including methyl, benzyl, and phenethyl moieties, had no effect on the potency
of the compound. Interestingly, after purification of the (R)- and (S)-isomers of 16G8,
activity against the LASV pseudotypes was fully retained with (S)-16G8, whereas (R)-16G8
showed 15-fold lower activity. This indicates that the stereochemistry of the molecule is
important for its function against arenavirus GP-mediated fusion. A similar effect was also
observed with 17C8, with (S)-17C8 being significantly more potent than (R)-17C8 against
LASV pseudotypes (Lee et. al., unpublished results). The requirement for one stereoisomer
over another suggests that our compounds bind to a specific structure on the GP to exert
their effects, and efforts to identify where the compounds bind the GP and block fusion are
currently underway.
Another screen for LASV entry inhibitors used a chemically diverse random library of
400,000 small molecule compounds and a lentivirus pseudotype platform (Larson et al.,
2008). Applying a more stringent cut-off (>75% inhibition at 5 μM), HTS resulted in a hit
rate of 1.2%. However, in contrast to the combinatorial library screen, where counter-
screens reduced the number of hits by less than 50% (Lee et al., 2008), 90-95% of the hits in
the random library screen were found to be not specific for LASV pseudotypes and/or
cytotoxic (Larson et al., 2008). The most promising hit, a unique benzimidazole derivative,
ST-37 (Fig. 2), exhibited an IC50 of 16 nM against LASV pseudotypes. Subsequent SAR
and lead optimization yielded the compound ST-193 (Fig. 2) that inhibited pseudotypes of
LASV, JUNV, MACV, GTOV, and SABV with IC50 of 2-12 nM (Larson et al., 2008). The
candidate ST-193 was also potent against live viruses, supporting the use of pseudotype
platforms for this type of screens. Mechanistic studies revealed that ST-193 and the formerly
identified New World arenavirus entry inhibitor ST-294 inhibit GP-mediated membrane
fusion (Larson et al., 2008; York et al., 2008). Interestingly, despite potent inhibition of cell
entry of hemorrhagic arenaviruses by 17C8 and ST-193, both compounds seem to be far less
active against LCMV, whose GP is structurally closely related to LASV (Larson et al.,
2008); Lee et al., unpublished results). The resistance of LCMV GP towards ST-193
mapped to the C-terminal portion of GP2 and involves two residues in the transmembrane
domain that show divergence between LCMV on the one hand and the hemorrhagic
arenaviruses, including LASV, on the other hand (Larson et al., 2008). In sum, two
independent small molecule screens using pseudotype platforms in combination with
different library formats identified a set of broadly active potent inhibitors of arenavirus
fusion. These studies provide proof-of-principle for this type of approach and establish
arenavirus membrane fusion as a robust drug target to combat a broad range of arenaviruses.
A notable strength of HTS of small molecule libraries is that no information on the structure
of the viral envelope protein, receptor use, and pathway of endocytosis is needed. This
approach holds therefore a great potential for the rapid discovery of cell entry inhibitors for
newly emerging enveloped viruses that allow pseudotyping.
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In addition to serving as promising leads for drug development against human pathogenic
arenaviruses, the prototypic fusion inhibitors identified by these recent studies can also be
used as molecular probes to dissect the mechanism of arenavirus membrane fusion. This is
of particular interest in the context of arenaviruses as studies over the past years revealed
unusual and unique features of arenavirus fusion that are not shared by other enveloped
viruses. The GPs of arenaviruses show overall similarity to fusion-active class I envelope
glycoproteins of other enveloped viruses (Eschli et al., 2006), but is unusual in that it
contains a stable signal peptide (SSP) of remarkable length that is retained as an essential
component of the fusion-active mature GP complex with the composition SSP/GP1/GP2
(Eichler et al., 2003; York et al., 2004). The arenavirus SSP contains 58 amino acids with
two putative transmembrane domains and both the N- and the C-terminus in the cytosol and
plays an important role in transport, maturation, and fusion-activity of the GP (Agnihothram,
York, and Nunberg, 2006; Agnihothram et al., 2007; Saunders et al., 2007; York and
Nunberg, 2006; York and Nunberg, 2007). In particular amino acid substitutions of the
conserved residue K33 in the short ectodomain loop of SSP modulate the fusion pH of
arenavirus GP, indicating an interaction between SSP and the fusion machinery of GP2. The
New World arenavirus entry inhibitor ST-294 has been used in mechanistic studies to
illuminate molecular details of JUNV fusion (York et al., 2008). Evidence was provided that
ST-294 acts as a fusion inhibitor, targeting the interaction of the fusion-active GP2 subunit
with SSP, and that amino acid substitutions at the residue K33 of SSP confer resistance to
ST-294. Both ST-294 and the broadly active arenavirus fusion inhibitor ST-193 inhibit
dissociation of GP1 from the SSP/GP1/GP2 complex induced by low pH, which occur
concomitant with conformational changes in the fusion-active GP2 part (York et al., 2008).
The proteolytic processing of arenavirus glycoprotein precursor as a novel target for anti-
viral therapy
A crucial step in the life cycle of arenaviruses is the proteolytic processing of the arenavirus
GP precursor (GPC) by the cellular protease SKI-1/S1P, yielding fusion-active, mature GP.
Processing of arenavirus GPC by SKI-1/S1P is essential for productive infection and viral
spread (Beyer et al., 2003; Kunz et al., 2003; Lenz et al., 2001; Rojek et al., 2008a). In the
host cell, SKI-1/S1P is involved in proteolytic processing of a defined set of cellular
proteins, including the sterol regulatory element-binding proteins (SREBP-1 and SREBP-2),
involved in lipid metabolism (Brown and Goldstein, 1997; Sakai et al., 1998), and the
activating transcription factor 6 (ATF6), involved in the regulation of the cellular unfolded
protein response (Schroder and Kaufman, 2005; Ye et al., 2000). Interestingly, apart from
the arenaviruses, SKI-1/S1P is also implicated in the proteolytic processing of the envelope
GPs of the highly pathogenic Bunyavirus Crimean Congo HF virus (Vincent et al., 2003).
Efforts to develop specific inhibitors of SKI-1/S1P resulted in the design of recombinant
serpins able to block SKI-1/S1P activity (Pullikotil et al., 2004). Expression of SKI-1/S1P-
adapted α1-antitrypsin variants efficiently inhibited the processing of LASV GPC and had a
pronounced impact on production of infectious LASV from infected cells (Maisa et al.,
2009). Another study evaluated a cell-permeable, peptide-based inhibitor that combines a
reactive chloromethylketone (CMK) moiety with peptides derived from the LASV GPC
recognition motif of SKI-1/S1P, decanoyl (dec)-RRLL-CMK (Pasquato et al., 2006; Rojek
et al., 2010). Dec-RRLL-CMK functions as a fast-acting suicide inhibitor of SKI-1/S1P
(Pasquato et al., 2006) and showed significant anti-viral effects against the prototypic
LCMV (Rojek et al., 2010). Off-target effects unrelated to SKI-1/S1P-mediated GPC
processing were excluded employing a recombinant LCMV variant bearing a canonical furin
recognition site (RRRR) in its GPC. Combination of the protease inhibitor with Rib resulted
in additive drug effects. Remarkably, in cells deficient in SKI-1/S1P, the furin-dependent
LCMV variant established persistent infection, whereas wild-type LCMV underwent
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extinction without emergence of SKI-1/S1P -independent escape variants. Together, these
studies strongly suggested that inhibitors of SKI-1/S1P protease represent promising and
powerful anti-arenaviral drug candidates.
The SKI-1/S1P-adapted serpins and the peptide inhibitor dec-RRLL-CMK used in these
proof-of-principle studies both have limitations in their potential use as an anti-viral in vivo.
Recently small molecule HTS performed by Pfizer Inc. identified a novel SKI-1/S1P
inhibitor, the amino-pyrrolidine amide compound PF-429242 (Hawkins et al., 2008; Hay et
al., 2007). PF-429242 blocked SKI-1/S1P-mediated processing of the transcription factor
SREBP in cell culture and treatment of mice with PF-429242 reduced expression levels of
hepatic SREBP target genes and lowered rates of cholesterol and fatty acid synthesis
(Hawkins et al., 2008). PF-429242 showed high stability, low toxicity and pharmacokinetic
properties that made it an interesting drug candidate in the context of arenavirus infection.
Indeed, PF-429242 efficiently prevented processing of GPC of LCMV and LASV, which
correlated with the compound's potent anti-viral activity against LCMV and LASV in
cultured cells (Urata et al., 2010). In contrast, a recombinant LCMV expressing a GPC
whose processing is mediated by furin was highly resistant to PF-429242 treatment.
Mechanistically, PF-429242 did not affect virus RNA replication or budding, and had an
only modest effect on virus cell entry, indicating that the anti-arenaviral activity of
PF-429242 was mostly related to its ability to inhibit SKI-1/S1P-mediated GPC processing.
These findings support the feasibility of using the small molecule SKI-1/S1P inhibitor
PF-429242 as a novel anti-arenaviral drug.
Since SKI-1/S1P plays an important role in a number of physiological processes, including
lipid metabolism and ER stress, the development of inhibitors that specifically target
processing of arenavirus GPC while having minimal effects on the processing SKI-1/S1P's
cellular substrates has of course highest priority. Nevertheless, SKI-1/S1P inhibitors like
PF-429242 are promising since hemorrhagic fevers caused by arenaviruses in humans are
acute diseases with a relatively rapid course of infection (Geisbert and Jahrling, 2004;
McCormick and Fisher-Hoch, 2002). Consequently, drug intervention to treat hemorrhagic
arenaviruses would be restricted to short period of times. Dietary supplementation of
cholesterol and other lipids to patients in intensive care appears feasible and would limit
unwanted side-effects of PF-429242 on lipid metabolism. Moreover, cells deficient in
SKI-1/S1P are still able mount a partial ER stress response (Ye et al., 2000), suggesting that
short term inhibition of the SKI-1/S1P activity may not result in unacceptable levels of
toxicity. Therefore, candidate drugs that lack absolute specificity and to some degree affect
the processing of cellular targets of S1P may still represent important candidates to be
evaluated as antiviral drugs.
Conclusions and Outlook
Considering the significance of arenaviruses as important public health problems, the
development of novel and potent anti-arenaviral drugs that can be manufactured at low costs
remains an urgent need. Small molecule HTS performed over the past years identified novel
classes of anti-viral drug candidates and provided proof-of-concept for the feasibility of this
strategy for anti-arenaviral drug discovery. The successful identification of potent and
specific inhibitors for arenavirus cell entry illustrate that small molecule HTS approaches for
anti-viral drug discovery require neither structural information on the virus, nor knowledge
on cellular factors involved. This type of approach is therefore highly suitable for rapid drug
development against newly emerging human pathogenic viruses, provided their envelope
proteins are amenable for pseudotyping. In addition to viral entry, virtually every step of the
arenavirus replication cycle could be targeted by this approach. The development of replicon
systems for LASV (Hass et al., 2004), as well as a novel and powerful cell-based luciferase
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assay suitable for HTS of inhibitors of arenavirus budding (Capul and de la Torre, 2008)
open the possibility to screen for compounds that act at additional steps in the viral life
cycle. The availability of inhibitors against distinct steps of viral multiplication would open
the possibility of combinatorial drug use, reducing the risk of emergence of drug-resistance.
The successful use of newly discovered arenavirus entry inhibitors to study mechanisms of
arenavirus fusion (York et al., 2008) highlights the potential of small molecule screens to
provide novel small molecule agonists and antagonists that can be used as molecular probes
to dissect biomolecular interactions. In particular the use of reversible small molecule
inhibitors with mid- to low nanomolar binding affinities and defined drug targets allows the
specific perturbation of molecular interactions in a dynamic manner due to micro-
reversibility of inhibition. Target-specific small molecule compounds identified in HTS may
thus complement other existing techniques such as genomic knock-out, RNA interference,
and perturbation by antibodies in studies of the molecular interactions underlying arenavirus
infection.
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Figure 1. Arenavirus particle and genome organization
(A) Schematic representation of an arenavirus particle. The viral RNA is packaged into
ribonucleoparticles (RNP) containing the viral nucleoprotein (NP). The RNA-dependent
RNA polymerase (L) is associated with RNP and required for initial steps of viral
transcription. The matrix protein Z associates with the inner leaflet of the viral membrane
envelope and interacts with the C-terminal part of the transmembrane GP2 moiety of the
mature GP decorating the virion surface. (B) The ambisense coding strategy of arenaviruses.
Each of the two single-stranded RNA segments, L and S, uses an ambisense coding strategy
to direct the synthesis of two polypeptides in opposite orientations and separated by an
intergenic region (IGR).
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Figure 2. Arenavirus entry inhibitors identified in small molecule HTS
(A) Arenavirus entry inhibitors identified by HTS of a random chemical library (Bolken et
al., 2006; Larson et al., 2008). (B) Inhibitors of arenavirus entry obtained from HTS of
combinatorial libraries (Lee et al., 2008). (C) SAR of the candidate compounds 17C8 and
16G8 obtained from the combinatorial library HTS (Lee et al., 2008). For details please see
text.
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